Gemphire to Present at the LD Micro Invitational and the Jefferies 2017 Global Healthcare Conference
June 01 2017 - 8:00AM
Gemphire Therapeutics Inc. (NASDAQ:GEMP), a clinical-stage
biopharmaceutical company focused on developing and commercializing
therapies for cardiometabolic disorders, including dyslipidemia and
NASH, today announced that management will provide a corporate
update at LD Micro Invitational, taking place June 6-7 in Los
Angeles, California, and at the Jefferies 2017 Global Healthcare
Conference, taking place June 6-9, 2017, in New York City.
LD
Micro Invitational |
Date: |
|
|
Tuesday, June 6th |
Time: |
|
|
4:00 pm Pacific
Time |
Presenter: |
|
|
Charles Bisgaier,
Ph.D., Chief Scientific Officer |
Location: |
|
|
Luxe Sunset Boulevard
Hotel, Los Angeles, CA |
|
|
|
|
Jefferies 2017 Global Healthcare Conference |
Date: |
|
|
Thursday, June 8th |
Time: |
|
|
4:00pm Eastern
Time |
Presenter: |
|
|
Lee Golden, MD, Chief
Medical Officer |
Location: |
|
|
Grand Hyatt Hotel,
Imperial Ballroom |
Webcast: |
|
|
http://wsw.com/webcast/jeff105/gemp |
About GemphireGemphire is a clinical-stage
biopharmaceutical company that is committed to helping patients
with cardiometabolic disorders, including dyslipidemia and
NASH. We are focused on providing new treatment options for
cardiometabolic diseases through our complementary, convenient,
cost-effective product candidate gemcabene as add-on to the
standard of care especially statins that will benefit patients,
physicians, and payors. Gemphire has 3 clinical trials
ongoing for homozygous familial hypercholesterolemia (HoFH),
heterozygous familial hypercholesterolemia (HeFH)/atherosclerotic
cardiovascular disease (ASCVD), and severe hypertriglyceridemia
(SHTG) under NCT02722408, NCT02634151, and NCT02944383,
respectively with a fourth planned trial in NASH in second half of
2017. Please visit www.gemphire.com for more information.
Contact:
Andrew McDonald, Ph.D.
LifeSci Advisors, LLC
(646) 597-6987
Jeff Mathiesen, CFO
Gemphire Therapeutics Inc.
(734)-245-1700
Gemphire Therapeutics (NASDAQ:GEMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gemphire Therapeutics (NASDAQ:GEMP)
Historical Stock Chart
From Apr 2023 to Apr 2024